Skip to main content
Caplight Logo









Rebirthel Co., Ltd.

Rebirthel Co., Ltd.

Private
KyotoHealthcare & Life Scienceshttps://rebirthel.com/en/

Last Round

Series B

Dec 1, 2022

Total Funding Raised

$1.7M

Company Overview

Rebirthel Co., Ltd. is a biotechnology company that develops allogeneic T-cell immunotherapies using iPS cells to treat cancer and other immune-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T cell therapyallogeneic cell therapyiPS cell technologyoff-the-shelf therapyinduced pluripotent stem cellsiPSCcancer immunotherapybiotech licensingcell therapy platformoncology R&Doff-the-shelf CAR-Tuniversal CAR-Tnext-gen cell therapybiotech collaboration

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rebirthel Co., Ltd. Comparables

Compare Rebirthel Co., Ltd. with similar companies based on industry and business-model similarity.

Rebirthel Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shoreline Biosciences
83%
Cartherics
83%
Neukio Biotherapeutics
83%

Rebirthel Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 1, 2022
SeedMar 30, 2020

Key People

Founding team and executive leadership

Masunori Kajikawa

President And Chief Executive Officer

Executive Team

Rebirthel Co., Ltd. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 10, 2025

    Partnering with Eutilex to develop next-generation CAR-T therapies.

  • Mar 30, 2020

    Secured funding from Japan Science and Technology Agency.

Rebirthel Co., Ltd. Filings

Explore SEC and related filing metadata, where available.

Rebirthel Co., Ltd. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Rebirthel Co., Ltd.'s valuation, stock price, and market status.

Is Rebirthel Co., Ltd. a public or private company?

Rebirthel Co., Ltd. is a private company.

What is the current stock price of Rebirthel Co., Ltd.?

Rebirthel Co., Ltd. is a private company with no public stock price. No recent secondary market data is available.

How much is Rebirthel Co., Ltd. worth (valuation)?

Valuation information for Rebirthel Co., Ltd. is not publicly available.

Can I buy Rebirthel Co., Ltd. stock?

Rebirthel Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Rebirthel Co., Ltd.'s last funding round?

Rebirthel Co., Ltd.'s most recent funding round was Series A on December 1, 2022.

Who are the main investors in Rebirthel Co., Ltd.?

Key investors in Rebirthel Co., Ltd. include Chushin Venture Capital, 株式会社ヘルスケア・イノベーション, Kagawa Securities Co., Ltd., Nissei Capital, Japan Science and Technology Agency.

Will Rebirthel Co., Ltd. IPO soon?

No public IPO plans have been announced for Rebirthel Co., Ltd..

How can I track Rebirthel Co., Ltd. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Rebirthel Co., Ltd.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersKyoto
Employee Range1
Year Founded2019
Last FundingDec 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?